Some of the key players in the market are:
Agfa-Gevaert N.V.
CardiArc Ltd.
Digirad Corporation
Gamma Medica Inc.
GE Healthcare
Hologic Inc.
Agfa-Gevaert N.V.
CardiArc Ltd.
Digirad Corporation
Gamma Medica Inc.
GE Healthcare
Hologic Inc.
The global market for radioisotopes is estimated to be USD
8.55 billion in 2014 and is expected to reach USD 15.37 billion by the end of
2019. During this period of forecast, the market is expected to grow at a CAGR
of 12.45%.
Global Nuclear Medicine Radioisotopes Market-Market Dynamics
The report details several factors driving and restraining the market. Some of these are listed below.
Drivers
Global Nuclear Medicine Radioisotopes Market-Market Dynamics
The report details several factors driving and restraining the market. Some of these are listed below.
Drivers
Major driving factors for the growth of the market are:
Increasing demand for SPECT and PET analysis in radiopharmaceuticals
Development of better instruments
Newer computer-based procedures for image analysis and display
New 99mTc labeled agents for visualizing biologically significant events
Increasing use in clinical applications to study psychiatric disorders
Integration of X-Ray tomography (CT) into SPECT
Restraints
Increasing demand for SPECT and PET analysis in radiopharmaceuticals
Development of better instruments
Newer computer-based procedures for image analysis and display
New 99mTc labeled agents for visualizing biologically significant events
Increasing use in clinical applications to study psychiatric disorders
Integration of X-Ray tomography (CT) into SPECT
Restraints
Some of the major constraints for the market are:
Shorter half-life of radioisotopes
High capital investment
Regulatory guidelines
Reimbursement issues
Shorter half-life of radioisotopes
High capital investment
Regulatory guidelines
Reimbursement issues
Request a sample of
this report @ http://www.orbisresearch.com/contacts/request-sample/219738 .
The market is segmented on the basis of the type of
radioisotopes, application, and geography. On the basis of the type of
radioisotopes, the market is segmented into Technetium-99m (TC-99m),
Thallium-201 (TL-201), Iodine (I-123), Fluorine-18, Rubidium-82 (RB-82) and
others. By application, the market is segmented into cardiology, lymphoma,
thyroid, neurology oncology, and others. By geography, the market is segmented
into North America, Europe, and Asia-Pacific.
SPECT radioisotopes chemical form of thallous chloride has been the principle tracer used in myocardial perfusion imaging. Technetium-99m is the major radioisotope used in SPECT. Generally, technetium is produced in technetium generators. Tl-201 is used in myocardial perfusion studies, In-111 is used in prostate cancer, and Ga-67 is used in lymphoma diagnosis and treatment. The most commonly used radiotracer in PET imaging is F-18 fluorodeoxyglucose (FDG), a glucose analogue. FDG-PET scans have been more accurate than conventional imaging in the evaluation of many malignancies. The other radionuclide used is Rubidium-82.
SPECT radioisotopes chemical form of thallous chloride has been the principle tracer used in myocardial perfusion imaging. Technetium-99m is the major radioisotope used in SPECT. Generally, technetium is produced in technetium generators. Tl-201 is used in myocardial perfusion studies, In-111 is used in prostate cancer, and Ga-67 is used in lymphoma diagnosis and treatment. The most commonly used radiotracer in PET imaging is F-18 fluorodeoxyglucose (FDG), a glucose analogue. FDG-PET scans have been more accurate than conventional imaging in the evaluation of many malignancies. The other radionuclide used is Rubidium-82.
PET imaging radioisotopes have many applications in clinical neurology, which involves movement disorders, epilepsy, brain tumors, dementia, stroke and neuronal plasticity. Future applications include early diagnosis of brain metastases, Parkinson syndromes and neurodegenerative disorders such as AD. The market for radioisotopes is expected to be larger in developing countries because of the increasing awareness among people for radioisotopes, increasing the incidence of chronic disease like cancer and increasing population.
Mergers and acquisitions of small and medium-sized manufacturers to enter the overseas market is a strategy adopted by multinational players.
Purchase a copy of
Global Nuclear Medicine Diagnostics Market visit @ http://www.orbisresearch.com/contact/purchase/219738
For more information
contact sales@orbisresearch.com .
What the Report Offers
Market definition global nuclear medicine radioisotopes market along with identification of key drivers and restraints for the market.
Market analysis for the nuclear medicine radioisotopes market with region-specific assessments and competition analysis on a global and regional scale.
Market definition global nuclear medicine radioisotopes market along with identification of key drivers and restraints for the market.
Market analysis for the nuclear medicine radioisotopes market with region-specific assessments and competition analysis on a global and regional scale.
Identification of factors instrumental in changing the
market scenario, rising prospective opportunities and identification of key
companies that can influence the market on a global and regional scale.
Extensively researched competitive landscape section with profiles of major companies along with their market share.
A comprehensive list of key market players along with the analysis of their current strategic interests and key financial information.
A comprehensive analysis of the major trends, innovations and associated prospects for market growth over the coming half a decade.
Extensively researched competitive landscape section with profiles of major companies along with their market share.
A comprehensive list of key market players along with the analysis of their current strategic interests and key financial information.
A comprehensive analysis of the major trends, innovations and associated prospects for market growth over the coming half a decade.
An ideal opportunity for industry consultants and other
interested and allied parties to gain a critical insight into the factors
driving and restraining the market, in addition to opportunities offered.
Wide-ranging information provided about the leading market players and the major strategies adopted by them.
Wide-ranging information provided about the leading market players and the major strategies adopted by them.
Browse Complete Report @ http://www.orbisresearch.com/reports/index/global-nuclear-medicine-diagnostics-market-spect-and-pet--analysis-and-forecasts-2017-2022
.
Some points from TOC:
1. Introduction
1.1 Market Definition
1.2 Market Size Estimation
1.1 Market Definition
1.2 Market Size Estimation
2. Research Methodology
3. Executive Summary
4. Market Overview
4.1 Definition of radiopharmaceuticals
4.2 Market Share Analysis
4.3 Market Drivers
4.3.1 Rising incidences of Cancer and Cardiac disorders
4.3.2 Development of better instruments
4.3.3 Increasing SPECT and PET applications
4.3.4 Growing Patient awareness
4.4 Market Restraints
4.41 Strict Regulatory Issues
4.4.2 Reimbursement Problems
4.5 Opportunities
4.5.1 Increasing Imaging Technologies
4.5.2 Potential Radioisotopes in pipeline
4.53 Increasing neurological applications
4.5.4 Cyclotron based production
4.1 Definition of radiopharmaceuticals
4.2 Market Share Analysis
4.3 Market Drivers
4.3.1 Rising incidences of Cancer and Cardiac disorders
4.3.2 Development of better instruments
4.3.3 Increasing SPECT and PET applications
4.3.4 Growing Patient awareness
4.4 Market Restraints
4.41 Strict Regulatory Issues
4.4.2 Reimbursement Problems
4.5 Opportunities
4.5.1 Increasing Imaging Technologies
4.5.2 Potential Radioisotopes in pipeline
4.53 Increasing neurological applications
4.5.4 Cyclotron based production
For any enquires
before buying, connect with us @ enquiry@orbisresearch.com
About Us:
Orbis Research (orbisresearch.com) is a
single point aid for all your market research requirements. We have vast
database of reports from the leading publishers and authors across the globe.
We specialize in delivering customized reports as per the requirements of our
clients. We have complete information about our publishers and hence are sure
about the accuracy of the industries and verticals of their specialization.
This helps our clients to map their needs and we produce the perfect required
market research study for our clients.
Contact Information:
Hector Costello
Senior Manager – Client Engagements
4144N Central Expressway,
Suite 600, Dallas,
Texas – 75204, U.S.A.
Phone No.: +1 (214) 884-6817; +9164101019
Follow Us on LinkedIn: https://www.linkedin.com/company/orbis-research
Follow us on Twitter:
https://twitter.com/orbisresearch
Like us on Facebook:
https://www.facebook.com/pages/Orbis-Research/820969017982115
No comments:
Post a Comment